Show simple item record

dc.contributor.authorKahraman, T.en_US
dc.contributor.authorGucluler, G.en_US
dc.contributor.authorSimsek, I.en_US
dc.contributor.authorYagci, F. C.en_US
dc.contributor.authorYildirim, M.en_US
dc.contributor.authorOzen, C.en_US
dc.contributor.authorDinc, A.en_US
dc.contributor.authorGursel, M.en_US
dc.contributor.authorIkromzoda, L.en_US
dc.contributor.authorSutlu, T.en_US
dc.contributor.authorGay, S.en_US
dc.contributor.authorGursel, I.en_US
dc.date.accessioned2018-04-12T11:05:11Z
dc.date.available2018-04-12T11:05:11Z
dc.date.issued2017-02en_US
dc.identifier.issn2001-3078
dc.identifier.urihttp://hdl.handle.net/11693/37177
dc.description.abstractBehçet's disease (BD) activity is characterised by sustained, over-exuberant immune activation, yet the underlying mechanisms leading to active BD state are poorly defined. Herein, we show that the human cathelicidin derived antimicrobial peptide LL37 associates with and directs plasma extracellular vesicles (EV) to immune cells, thereby leading to enhanced immune activation aggravating BD pathology. Notably, disease activity was correlated with elevated levels of circulating LL37 and EV plasma concentration. Stimulation of healthy PBMC with active BD patient EVs induced heightened IL1β, IFNα, IL6 and IP10 secretion compared to healthy and inactive BD EVs. Remarkably, when mixed with LL37, healthy plasma-EVs triggered a robust immune activation replicating the pathology inducing properties of BD EVs. The findings of this study could be of clinical interest in the management of BD, implicating LL37/EV association as one of the major contributors of BD pathogenesis.en_US
dc.language.isoEnglishen_US
dc.source.titleJournal of Extracellular Vesiclesen_US
dc.relation.isversionofhttps://doi.org/10.1080/20013078.2017.1284449en_US
dc.subjectAutoimmuneen_US
dc.subjectBehçet's diseaseen_US
dc.subjectCytokineen_US
dc.subjectExtracellular vesiclesen_US
dc.subjectImmune activationen_US
dc.subjectLL37en_US
dc.subjectAlpha interferonen_US
dc.subjectBiological markeren_US
dc.subjectCathelicidinen_US
dc.subjectCathelicidin antimicrobial peptide LL 37en_US
dc.subjectGamma interferon inducible protein 10en_US
dc.subjectGlucose regulated protein 94en_US
dc.subjectInterleukin 10en_US
dc.subjectInterleukin 1betaen_US
dc.subjectInterleukin 6en_US
dc.subjectProtein Alixen_US
dc.subjectUnclassified drugen_US
dc.subjectAllogeneic extracellular vesicleen_US
dc.subjectArticleen_US
dc.subjectAutologous extracellular vesicleen_US
dc.subjectBehcet diseaseen_US
dc.subjectCell stimulationen_US
dc.subjectComparative studyen_US
dc.subjectComplex formationen_US
dc.subjectControlled studyen_US
dc.subjectCytokine productionen_US
dc.subjectCytokine releaseen_US
dc.subjectDisease activityen_US
dc.subjectDisease associationen_US
dc.subjectDisease severityen_US
dc.subjectExosomeen_US
dc.subjectHumanen_US
dc.subjectHuman cellen_US
dc.subjectImmune activationen_US
dc.subjectImmune responseen_US
dc.subjectImmunocompetent cellen_US
dc.subjectIncubation timeen_US
dc.subjectInternalizationen_US
dc.subjectPathogenesisen_US
dc.subjectPeripheral blood mononuclear cellen_US
dc.subjectPlasma extracellular vesicleen_US
dc.subjectPlasmacytoid dendritic cellen_US
dc.titleCirculating LL37 targets plasma extracellular vesicles to immune cells and intensifies Behçet's disease severityen_US
dc.typeArticleen_US
dc.departmentDepartment of Molecular Biology and Genetics
dc.citation.spage1284449-1en_US
dc.citation.epage1284449-13en_US
dc.citation.volumeNumber6en_US
dc.citation.issueNumber1en_US
dc.identifier.doi10.1080/20013078.2017.1284449en_US
dc.publisherTaylor and Francisen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record